FPR2 and Alzheimer disease: Still, surprisingly, when APP/PS1 double-transgenic AD mice were treated for 20 weeks with the anti-inflammatory FPR2 agonist Ac2-26, Ac2-26-treatment did not show any beneficial effect [92].